Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT05464082

Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC

Conditions: Breast Cancer Recurrent

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE2

Enrollment: 80

Sponsor: University of Utah

Location: Huntsman Cancer Institute at University of Utah Salt Lake City Utah

Summary

This is a prospective phase 2 study to use Functional Precision Oncology (FPO) to predict, prevent and treat early metastatic recurrence in subjects with HR-low/Her2 negative or triple negative breast cancer.

Eligibility Criteria

Registration: Pre-tumor Collection Eligibility Participant Inclusion Criteria * Subject aged ≥ 18 years. * Subject has Stage I-III disease. * Histologically or cytologically confirmed invasive breast carcinoma that is triple negative (TNBC) or hormone receptor (HR)-low/Her2 negative --TNBC is defined as: * HER2 expression 0 or 1+ on immunohistochemistry (IHC) or non-amplified (defined as HER2/CEP17 ratio \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05464082). StuddyBuddy aggregates publicly available trial information.